Guardant gets hit with a $245M patent bill

Ouch, that’s a lot of DNA drama

Guardant Health just got handed a courtroom bill that could make your eyes water: more than $245.2 million in damages after a U.S. court found the company infringed patents tied to DNA sequencing technology.

Why investors should care

This isn’t just legal trivia. A ruling like this can pressure cash flow, add settlement or appeals risk, and hang over the stock like a thundercloud with a legal brief.

• The plaintiffs: TwinStrand Biosciences and the University of Washington
• The issue: patents covering DNA sequencing technology
• The tab: more than $245.2 million

The bigger picture

For a company in diagnostics, intellectual property is basically part of the moat. Lose a patent battle and suddenly the moat looks a little more like a puddle. If Guardant appeals, the saga could drag on; if it pays up, that’s a meaningful hit investors will have to model in.

Big picture: in biotech, the science is hard — and apparently, the legal bills can be even harder.